Year: 2009
Type: book
Abstract: KCE reports 100C ICERs and ICER threshold values i FOREWORDThe Belgian Health Care Knowledge Centre is currently in its fifth year of performing Health Technology Assessments (HTA).HTA reports frequently contain an economic evaluation.In cases where an intervention offers better health outcomes at a higher cost than the best alternative intervention for the same condition, an incremental costeffectiveness ratio (ICER) is presented.The ICER reflects the additional cost for an additional unit of the health effect.It remains unclear, however, how Belgian decision makers deal with this kind of information.This report is an introduction to the methodological background, the value of ICERs and ICER threshold values and the discussion issues related to their use.The report also explores current knowledge and use of ICERs by Belgian health care decision makers.We highly value and acknowledge the collaboration with the Belgian Drug Reimbursement Committee and the Technical Council for Implants and the input we received from the participants to the interviews.This report is a methodological report comparable to the guidelines for pharmacoeconomic evaluations in Belgium (KCE report 78C).Since their publication in April 2008, the National Institute for Health and Disability Insurance (NIHDI) encourages the pharmaceutical companies to follow these guidelines when submitting a pharmacoeconomic evaluation as part of a drug reimbursement request.With this current report we hope to inform policy makers and other stakeholders about the use and relevance of economic evaluations for health care policy decisions and to improve policy makers' understanding of difficult economic concepts and study results.
DOI: 10.57598/r100c
Institution: Belgian Health Care Knowledge Centre (KCE)
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: gold
OpenAlex ID: W4406861950